Carlos M. Galmarini - Concepedia

Author

Carlos M. Galmarini

Also Known As

C Galmarini, C M Galmarini, C. Galmarini, C. M. Galmarini, C.M. Galmarini, CARLOS M. GALMARINI, CM Galmarini, Carlos Galmarini, Carlos M Galmarini, Carlos M. Galmarini

319

Publications

9.9K

Citations

H-Index

Concepts

All Affiliations

PharmaMar (Spain)Inserm Université Claude Bernard Lyon 1 Centre National de la Recherche Scientifique Centre Léon Bérard

About

Carlos M. Galmarini is an author at PharmaMar (Spain) specializing in medicine, cancer research, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	36	2.8K
2	Natural Sciences	5	5	187
3	Health Sciences	3	3	69
4	Engineering	1	1	27
5	Allergy Medicine	1	1	12

Carlos M. Galmarini

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin Giovanni Germano, Roberta Frapolli, Cristina Belgiovine, Cancer Cell Cancer ImmunosurveillanceDrug TargetingImmunologyImmunotherapyMedicine	2013	847
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells Giovanni Germano, Roberta Frapolli, Matteo Simone, Cancer Research InflammationTumor BiologyMyxoid LiposarcomaAnti-inflammatoryCancer Immunosurveillance	2010	263
<i>In vivo</i> mechanisms of resistance to cytarabine in acute myeloid leukaemia Carlos M. Galmarini, Xavier Thomas, Fabien Calvo, British Journal of Haematology	2002	159
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models Cristina Belgiovine, Ezia Bello, Manuela Liguori, British Journal of Cancer	2017	149
Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells Gema Santamaría Núñez, Carlos Mario Genes Robles, Christophe Giraudon, Molecular Cancer Therapeutics Tumor XenograftsMolecular BiologyCell DeathPol IiCancer Biology	2016	148
Cancer chemotherapy: A critical analysis of its 60 years of history Darío Galmarini, Carlos M. Galmarini, Felipe C. Galmarini Critical Reviews in Oncology/Hematology MedicinePharmacologyPathologyBreast CancerCritical Analysis	2012	137
Mode of action of trabectedin in myxoid liposarcomas Silvia Di Giandomenico, Roberta Frapolli, Ezia Bello, Oncogene Surgical PathologyHistopathologyPathologyTrabecular MeshworkMedicine	2013	128
Potential mechanisms of resistance to cytarabine in AML patients Carlos M. Galmarini, Xavier Thomas, Fabien Calvo, Leukemia Research PharmacologyAml PatientsPharmacotherapyMedicineTherapy Resistance	2002	126
Expression of a non‐functional p53 affects the sensitivity of cancer cells to gemcitabine Carlos M. Galmarini, Marilyn L. Clarke, Nicole Falette, International Journal of Cancer	2001	98
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin José Luis Ordóñez, Ana Teresa Amaral, Ángel M. Carcaboso, Oncotarget	2015	96

Page 1